Latent Raises $80M to Close the Gap Between Diagnosis and Treatment

Latent, the clinical-AI company accelerating access to life-saving medications, led by Sriram Somasundaram, Rishabh Jain, and the team, has raised an $80M Series A co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. Today, Latent works with 50% of the top 20 U.S. health systems.

Modern medicine has outpaced the systems that deliver it. In the U.S., even after a doctor prescribes treatment, 42% of critical cases face delays or denials, not due to medical gaps, but because therapies must navigate complex documentation, payer rules, and pharmacy coordination.

This process is still driven by manual, high-stakes clinical work, interpreting labs, applying treatment criteria, and aligning diagnoses with coverage, often across fragmented systems.

For the first time, AI offers a path to bridge this gap, bringing treatment decisions closer to actual patient care delivery.

Latent is building a Clinical Reasoning Engine that performs complex clinical knowledge work, analyzing patient data, interpreting drug criteria, extracting evidence, and orchestrating workflows across stakeholders.

By connecting EHRs, payer guidelines, pharmacy operations, and patient engagement into a unified system, the platform replaces fragmented manual processes with AI agents that move patients from diagnosis to treatment the same day.

The company began with prior authorization, one of healthcare’s most complex and high-stakes bottlenecks, and is now expanding across workflows where clinical knowledge must be translated into action.

Today, over 2 million patients are accessing treatment faster through Latent. The company has scaled from 4 to more than 45 health system partners, serving 50% of the top 20 U.S. systems, including Yale New Haven Health, Ochsner Health, Vanderbilt Health, Mount Sinai Health System, UCSF Health, and UCLA Health. Across specialties, it reduces denials by over 30% and enables clinicians to serve twice as many patients.

Looking ahead, the Clinical Reasoning Engine will be applied proactively to identify when patients should begin therapy and ensure adherence, addressing delays, denials, and missed treatments. The company is building infrastructure that connects clinicians, patients, and payers, powering the decisions that determine care delivery.

With its Series A, Latent will expand its health system footprint, deepen platform integrations across hospitals, payers, and pharmacies, invest in reliability and trust, and scale its team.